GenfitGNFT
About: Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Employees: 180
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.31% less ownership
Funds ownership: 0.42% [Q1] → 0.11% (-0.31%) [Q2]
13% less funds holding
Funds holding: 8 [Q1] → 7 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
73% less capital invested
Capital invested by funds: $740K [Q1] → $202K (-$538K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Brandon Folkes | 120%upside $9 | Buy Assumed | 19 Aug 2025 |
Financial journalist opinion









